Riduzione del ricircolo sanguigno nell'ECMO veno-venoso
Riduzione del ricircolo del sangue nell'ECMO veno-venoso attraverso misurazioni della diluizione degli ultrasuoni (ECMO Circulation Study)
Blood which recirculates through the circuit of a veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) does not contribute to the systemic oxygenation of a patient on V-V ECMO and is called the recirculation fraction (Rf). Theoretically, the optimization of ECMO blood flow is possible using Rf measurements.
A prospective, observational study will be performed measuring the Rf of total ECMO blood flow in patients with acute respiratory distress syndrome (ARDS) on V-V ECMO with an ultrasound dilution technique.
ECMO blood flow will be optimized by reducing ECMO blood flow in accordance with the measured Rf as long as systemic oxygenation is not compromised.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Descrizione dettagliata
Based on data from the 'Blood Recirculation and vvECMO' trial (ClinicalTrials.gov ID: NCT03200314) (i.e. an expected frequency of successful blood flow reduction of 66.7%), using a one-sample Chi square test, a two-sided type-1 error of 5%, a power of 80%, a total of 68 patients is needed to show that the proportion of patients with a secure ECMO blood flow reduction is greater than 50%. Presumably, 136 Patients have to be included into the trial to study 68 patients with a relevant Rf since not all patients on V-V ECMO suffer from a high Rf.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
State of Berlin
-
Berlin, State of Berlin, Germania, 13353
- Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Inclusion Criteria:
- patients aged 18 years or older
- ARDS
- veno-venous ECMO
Exclusion Criteria:
- age < 18 years
- hemodynamic instability during measurement of recirculation
- pregnancy
- inability to obtain patient's consent or consent of legal guardian
Descrizione
Patients aged 18 years or older requiring veno-venous ECMO for treatment of refractory hypoxemia in ARDS.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Successful ECMO blood flow reduction
Lasso di tempo: Once within the first week after initiation of ECMO therapy
|
Number of patients with a relevant recirculation fraction and successful ECMO blood flow reduction |
Once within the first week after initiation of ECMO therapy
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Recirculation fraction
Lasso di tempo: Once within the first week after initiation of ECMO therapy
|
Fraction of blood recirculating through the ECMO circuit |
Once within the first week after initiation of ECMO therapy
|
|
Arterial blood oxygen content
Lasso di tempo: Once within the first week after initiation of ECMO therapy
|
Arterial blood oxygen content before vs. after reduction of ECMO blood flow |
Once within the first week after initiation of ECMO therapy
|
|
Extracorporeal blood Flow
Lasso di tempo: Once within the first week after initiation of ECMO therapy
|
ECMO Blood Flow before vs. after reduction of ECMO blood flow |
Once within the first week after initiation of ECMO therapy
|
|
Extracorporeal gas flow
Lasso di tempo: Once within the first week after initiation of ECMO therapy
|
ECMO Sweep Gas flow |
Once within the first week after initiation of ECMO therapy
|
|
Length of ECMO therapy
Lasso di tempo: Daily until the end of ECMO therapy (approximately 14 days)
|
Days on ECMO |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
Cannula position and distance
Lasso di tempo: Once within the first week after initiation of ECMO therapy
|
The distance between the tip of drainage and return cannula will be measured in the existing medical imaging (e.g. CT scans) |
Once within the first week after initiation of ECMO therapy
|
|
Right heart dysfunction
Lasso di tempo: Once within the first week after initiation of ECMO therapy
|
Existing echocardiography will be evaluated for possible right heart dysfunction |
Once within the first week after initiation of ECMO therapy
|
|
Length of mechanical ventilation
Lasso di tempo: Entire duration of the ICU stay (approximately 28 days)
|
Length of mechanical ventilation |
Entire duration of the ICU stay (approximately 28 days)
|
|
Complications of ECMO therapy
Lasso di tempo: Length of ECMO therapy (approximately 14 days)
|
Incidence of cannula or system changes (i.e. due to circuit clotting), complications attributed to ECMO therapy like bleeding complications from the cannulation site, transfusion requirements, hemolysis |
Length of ECMO therapy (approximately 14 days)
|
|
ICU mortality
Lasso di tempo: Entire duration of the ICU stay (approximately 28 days)
|
ICU mortality |
Entire duration of the ICU stay (approximately 28 days)
|
|
ICU length of stay
Lasso di tempo: Entire duration of the ICU stay (approximately 28 days)
|
ICU length of stay |
Entire duration of the ICU stay (approximately 28 days)
|
|
Incidence of ICU-acquired organ dysfunctions and complications
Lasso di tempo: Entire duration of the ICU stay (approximately 28 days)
|
Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions, ICU-acquired infections |
Entire duration of the ICU stay (approximately 28 days)
|
|
ECMO blood flow over time
Lasso di tempo: Daily until the end of ECMO therapy (approximately 14 days)
|
ECMO blood and sweep gas flow over time |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
ECMO sweep gas flow over time
Lasso di tempo: Daily until the end of ECMO therapy (approximately 14 days)
|
ECMO sweep gas flow over time |
Daily until the end of ECMO therapy (approximately 14 days)
|
|
Mobility at ICU discharge
Lasso di tempo: Discharge from the ICU (approximately 28 days)
|
Level of mobility the patient has reached at ICU discharge (recumbent, sitting, standing, walking with help, walking independently) |
Discharge from the ICU (approximately 28 days)
|
|
Weaning level at ICU discharge
Lasso di tempo: Discharge from the ICU (approximately 28 days)
|
Level of weaning reached at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Status of mechanical ventilation at ICU discharge
Lasso di tempo: Discharge from the ICU (approximately 28 days)
|
Status of mechanical ventilation at ICU discharge including all relevant settings and parameters |
Discharge from the ICU (approximately 28 days)
|
|
Level of organ dysfunction at ICU discharge
Lasso di tempo: Discharge from the ICU (approximately 28 days)
|
Sepsis-related Organ Failure Assessment Score at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Level of consciousness at ICU discharge
Lasso di tempo: Discharge from the ICU (approximately 28 days)
|
Glasgow Coma Scale at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Level of disease severity
Lasso di tempo: Discharge from the ICU (approximately 28 days)
|
Acute Physiology And Chronic Health Evaluation at ICU discharge |
Discharge from the ICU (approximately 28 days)
|
|
Hospital acquired infections related to ECMO therapy
Lasso di tempo: Entire duration of ECMO therapy
|
Infection/colonisation of the ECMO circuit |
Entire duration of ECMO therapy
|
|
Bleeding and thrombembolic complications of ECMO therapy
Lasso di tempo: Entire duration of ECMO therapy
|
Bleeding complications, thrombembolic events, overall use of blood products and coagulation factors, electron microscopic evaluation of selected membranes after change or weaning of the ECMO circuit |
Entire duration of ECMO therapy
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Martin Russ, Dr. med., Charite University Hospital Berlin
- Investigatore principale: Philipp A Pickerodt, Dr. med., Charite University Hospital Berlin
- Investigatore principale: Vladimir Skrypnikov, Dr. med., Charite University Hospital Berlin
- Investigatore principale: Steffen Weber-Carstens, Prof. Dr. med., Charite University Hospital Berlin
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- EA115620
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .